Cerebral palsy


Cerebral Palsy

Endpoint parameters

Neutrojen C 130 Supraselective
(Intrathecal- Lumbar spinal injection)

Neutrojen C 130 Proprietary biologic / Bone Marrow derived mononuclear cells (autologous trial)

1Y: 30D, 3M, 6M, 12M Baseline diagnostic tests, Gadolinium MRI Brain & Spine, tests for recognized genetic mutations, Gross Motor Function Classification System (GMFCS) scale, 25 foot walk test (ambulatory subjects), end-point MRI

Neurogenesis and Revascularization, GMFCS improvement, improved walking gate, walk-time, marked motor, sensory, cognitive, speech amelioration, improved bowel and bladder control, change in lesion volume

Inclusion criteria: Spastic Cerebral Palsy; (Ag15-30) Ultrasound/CTV/MRV negative for CCSVI, Spinal stenosis (Myelopathy) negative, no family history of CP, Fragile X syndrome, tuberous sclerosis, down syndrome and other chromosomal disorders, human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus, malignancies, bleeding tendencies, pneumonia, renal failure, severe liver dysfunction, severe anemia [Hemoglobin < 8], other acute medical conditions such as respiratory infection and pyrexia may disqualify participants, recognized genetic mutations may disqualify patients

Our Physicians will walk you through each step of the application!

To learn more..
Inquire Now